Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 291 of the 291 references it cites were found in a registry or an index.

UK clinical guideline for the prevention and treatment of osteoporosis

Open access

Abstract

Summary: The National Osteoporosis Guideline Group (NOGG) has revised the UK guideline for the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. Accredited by NICE, this guideline is relevant for all healthcare professionals involved in osteoporosis management. Introduction: The UK National Osteoporosis Guideline Group (NOGG) first produced a guideline on the prevention and treatment of osteoporosis in 2008, with updates in 2013 and 2017. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. Methods: Where available, systematic reviews, meta-analyses and randomised controlled trials were used to provide the evidence base. Conclusions and recommendations were systematically graded according to the strength of the available evidence. Results: Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, and models of care for fracture prevention. Recommendations are made for training; service leads and commissioners of healthcare; and for review criteria for audit and quality improvement. Conclusion: The guideline, which has received accreditation from the National Institute of Health and Care Excellence (NICE), provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals involved in its management. This position paper has been endorsed by the International Osteoporosis Foundation and by the European Society for the Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11657-022-01061-5

Cites

291 of 291 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 NOGG assessment, intervention, and risk thresholds for major osteoporotic fracture probability (MOF) in the UK with the use of FRAX. Individuals with probabilities below the lower assessment threshold (LAT) are considered for lifestyle advice. Those at intermediate risk (probabilities between the upper assessment threshold (UAT) and lower assessment threshold (LAT) are further assessed with BMD measurement. Where probabilities calculated using BMD lie above or below the intervention threshold (IT), treatment or lifestyle advice, respectively, is recommended [3, 79]. Patients with probabilities above the upper assessment threshold (UAT) are considered for treatment. Those with probabilities above the very high-risk threshold (VHRT) should be considered for specialist referral. Where BMD measurement is not practical (e.g., when individuals are frail and unable to get onto a DXA table, or lie flat on a DXA table), patients with probabilities above the IT are considered for treatment
Fig. 1 NOGG assessment, intervention, and risk thresholds for major osteoporotic fracture probability (MOF) in the UK with the use of FRAX. Individuals with probabilities below the lower assessment threshold (LAT) are considered for lifestyle advice. Those at intermediate risk (probabilities between the upper assessment threshold (UAT) and lower assessment threshold (LAT) are further assessed with BMD measurement. Where probabilities calculated using BMD lie above or below the intervention threshold (IT), treatment or lifestyle advice, respectively, is recommended [3, 79]. Patients with probabilities above the upper assessment threshold (UAT) are considered for treatment. Those with probabilities above the very high-risk threshold (VHRT) should be considered for specialist referral. Where BMD measurement is not practical (e.g., when individuals are frail and unable to get onto a DXA table, or lie flat on a DXA table), patients with probabilities above the IT are considered for treatmentCC BY · PubMed Central
Fig. 2 NOGG thresholds for intervention and/or referral using major osteoporotic fracture (MOF) and hip fracture (HF) probabilities in the UK. The panels show the thresholds following the recalculation of FRAX after the input of BMD; the same thresholds are used when BMD is unavailable. The intervention threshold (IT) and very high-risk threshold (VHRT) denote the thresholds for high and very high risk, respectively
Fig. 2 NOGG thresholds for intervention and/or referral using major osteoporotic fracture (MOF) and hip fracture (HF) probabilities in the UK. The panels show the thresholds following the recalculation of FRAX after the input of BMD; the same thresholds are used when BMD is unavailable. The intervention threshold (IT) and very high-risk threshold (VHRT) denote the thresholds for high and very high risk, respectivelyCC BY · PubMed Central
Fig. 3 Management algorithm for the assessment of individuals at risk of fracture [130]. Those at very high risk should be treated and considered for referral to an osteoporosis specialist in secondary care; some may benefit from parenteral treatment (including first-line anabolic drug treatment, especially if multiple vertebral fractures). All individuals should be offered lifestyle advice. CRF, clinical risk factor
Fig. 3 Management algorithm for the assessment of individuals at risk of fracture [130]. Those at very high risk should be treated and considered for referral to an osteoporosis specialist in secondary care; some may benefit from parenteral treatment (including first-line anabolic drug treatment, especially if multiple vertebral fractures). All individuals should be offered lifestyle advice. CRF, clinical risk factorCC BY · PubMed Central
Fig. 4 Oral Bisphosphonates: clinical flowchart for long-term treatment and monitoring. GC, glucocorticoids (oral ≥ 7.5 mg prednisolone/day or equivalent). BP, bisphosphonate
Fig. 4 Oral Bisphosphonates: clinical flowchart for long-term treatment and monitoring. GC, glucocorticoids (oral ≥ 7.5 mg prednisolone/day or equivalent). BP, bisphosphonateCC BY · PubMed Central
Fig. 5 Intravenous Bisphosphonates: clinical flowchart for long-term treatment and monitoring. GC, glucocorticoids (oral ≥ 7.5 mg prednisolone/day or equivalent). BP, bisphosphonate
Fig. 5 Intravenous Bisphosphonates: clinical flowchart for long-term treatment and monitoring. GC, glucocorticoids (oral ≥ 7.5 mg prednisolone/day or equivalent). BP, bisphosphonateCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 290 references

Research works printed but not linked: 5

  1. Royal College of Physicians (2021) The challenge of the next decade: are hip fracture services ready? A review of data from the National Hip Fracture Database (January–December 2019). RCP, London
  2. Department of Health (1991) Dietary reference values for food energy and nutrients for the United Kingdom. HMSO, London
  3. Min W, An R, Li S, Feng J, Yang J, Huang Z (2017) The effects of preoperative smoking cessation on the healing of fractures and postoperative complications: a systematic review and meta-analysis. Biomed Res 28:1883–1889
  4. Health. Do (2016) UK Chief Medical Officers’ Alcohol Guidelines Review Summary of the proposed new guidelines. Williams Lea
  5. Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211 · doi:10.1002/1529-0131(200101)44:1<202::aid-anr27>3.0.co;2-w

Cited by

See all 654

Metadata

Authors
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., McCloskey, E., Moss, K., Parker, J., Paskins, Z., Poole, K., Reid, D. M., Stone, M., Thomson, J., Vine, N., & Compston, J.
Affiliations
  • Royal United Hospital (GB)
  • University of Ulster (GB)
  • Southmead Hospital (GB)
  • University Hospital Southampton NHS Foundation Trust (GB)
  • Arthritis UK (GB)
  • Queen Elizabeth Hospital Birmingham (GB)
  • Australian Catholic University (AU)
  • Royal Osteoporosis Society (GB)
  • Nuffield Orthopaedic Centre (GB)
  • St George's Hospital (GB)
  • University of Cambridge (GB)
  • University of Aberdeen (GB)
  • Cardiff and Vale University Health Board (GB)
Corresponding author
Gregson, Celia L.
Venue
Archives of Osteoporosis
Published
2022-04-05
Volume
17
Issue
1
Pages
58-58
ISSN
  • 1862-3514 (ISSN-L)
  • 1862-3522
OpenAlex
W4226048997
Cited by
593
References
290
Citations by year
2026: 77 · 2025: 177 · 2024: 165 · 2023: 113 · 2022: 33
FWCI
126.48
Type
journal article
Language
en
Open access
Licence
Locations
  • Archives of Osteoporosis (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Explore Bristol Research (publishedVersion, cc-by)
  • ePrints Soton (University of Southampton) (acceptedVersion)
  • St George's Online Research Archive (St George's University of London) (acceptedVersion)
  • Ulster University Research Portal (Ulster University) (submittedVersion, cc-by)
Funders
National Institute for Health Research (CS-2018-18-ST2-010)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
osteoporosis, osteoporosis prevention, osteoporosis treatment, fragility fractures, postmenopausal women, older men, fracture risk assessment, vertebral fractures, antiresorptive therapy, glucocorticoid-induced osteoporosis, non-pharmacological treatment, models of care, osteoporosis diagnosis
MeSH terms
Female, United Kingdom, Humans, Male, Middle Aged, Osteoporosis, Bone Density, Risk Assessment, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: UK clinical guideline for the prevention and treatment of osteoporosis. https://app.cochat.ai/papers/10.1007/s11657-022-01061-5
The paper
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., McCloskey, E., Moss, K., Parker, J., Paskins, Z., Poole, K., Reid, D. M., Stone, M., Thomson, J., Vine, N., & Compston, J. (2022). UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis. https://doi.org/10.1007/s11657-022-01061-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.